NCT03494504Phase 3Completed

ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic Conjunctivitis

Study sponsor: Aldeyra Therapeutics, Inc. · ALDX

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2018-11-05Actual

Enrollment · participants318Actual

Source updated2025-02-11Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Allergic Conjunctivitis

Treatments or interventions studied

Reproxalap Ophthalmic Solution (0.25%)Drug
Reproxalap Ophthalmic Solution (0.5%)Drug
Vehicle Ophthalmic SolutionDrug

Primary outcomes · main study measures

Read the study measures

measure: Subject-reported Ocular Itching Score; description: Subject-reported ocular itching score area under the curve from 10 to 60 minutes post allergen challenge using a 0 to 4 scale (0 = none, 4 = severe) was assessed. The least squares mean was derived from analysis of covariance of area under the curve with baseline as a covariate and treatment as a fixed effect The possible range for area under the curve least squares mean is 0 to 100, where a lower score is better.; timeFrame: Efficacy was assessed after a single dose; baseline was assessed approximately two weeks before dosing.

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history